What one share of Eupraxia Pharmaceuticals holds
On January 8, 2026, the Company announced positive tissue health data from its ongoing RESOLVE trial in EoE including the demonstration of near-complete improvement on biopsy in the highest dosed group.
Eupraxia Pharmaceuticals’s numbers from its SEC filings, divided by its shares. Results cover the latest fiscal year to 2025-12-31; the balance sheet is as of 2025-12-31.
| Sales | $0.00 |
|---|---|
| Profit | −$1.03 |
| Cash and investments | $1.55 |
| Book value | $1.58 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2022 | — | −$0.96 | — | — | — | $0.36 |
| 2023 | $0.00 | −$1.17 | — | — | — | $0.08 |
| 2024 | $0.00 | −$0.76 | — | — | — | $0.94 |
| 2025 | $0.00 | −$1.03 | — | — | — | $1.58 |
Common questions about Eupraxia Pharmaceuticals
How much does one share of Eupraxia Pharmaceuticals earn?
Over its latest fiscal year, Eupraxia Pharmaceuticals lost $1.03 for each share.
Does Eupraxia Pharmaceuticals pay a dividend?
Eupraxia Pharmaceuticals didn’t pay a dividend over its latest fiscal year, according to its SEC filings.
What is Eupraxia Pharmaceuticals’s book value per share?
Eupraxia Pharmaceuticals’s book value is $1.58 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of December 31, 2025.
How much cash and debt does each share of Eupraxia Pharmaceuticals have?
Each share of Eupraxia Pharmaceuticals has $1.55 of cash and investments, as of December 31, 2025.
Has Eupraxia Pharmaceuticals bought back shares?
Eupraxia Pharmaceuticals’s share count rose about 107% from 2022 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.